KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBITDA (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of EBITDA data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, EBITDA fell 90.53% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $19.2 million, up 126.16%, while the annual FY2025 figure was $19.2 million, 126.16% up from the prior year.
  • EBITDA reached $2.3 million in Q4 2025 per PCRX's latest filing, down from $6.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $39.9 million in Q2 2023 and bottomed at -$139.5 million in Q3 2024.
  • Average EBITDA over 5 years is $9.2 million, with a median of $17.6 million recorded in 2022.
  • Peak YoY movement for EBITDA: skyrocketed 587.52% in 2021, then crashed 887.35% in 2024.
  • A 5-year view of EBITDA shows it stood at $4.2 million in 2021, then crashed by 334.93% to -$9.9 million in 2022, then surged by 435.27% to $33.2 million in 2023, then fell by 25.52% to $24.7 million in 2024, then tumbled by 90.53% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $2.3 million in Q4 2025, $6.4 million in Q3 2025, and $8.5 million in Q2 2025.